Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Diametrics

This article was originally published in The Gray Sheet

Executive Summary

Submits 510(k) for its Neurotrend monitoring system for measuring oxygen, carbon dioxide, acidity and temperature of the brain in patients with severe head injuries and during brain surgery. The new market segment for Diametrics could surpass $100 mil., the firm states. Multi-center trials by neurosurgeons for Neurotrend are in process. Diametrics says the trials are "demonstrating the significant clinical benefit of this system"...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel